COMMUNIQUÉS West-GlobeNewswire

Pacira BioSciences Announces First Patient Dosed in Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee

03/04/2025 - 14:00

-- Novel, locally administered gene therapy designed to boost cellular production of anti-inflammatory protein IL-1Ra in the knee -- -- Initial topline results from two-part, randomized, double-blind, active-controlled [...]

TerrAscend to Host First Quarter 2025 Earnings Conference Call

03/04/2025 - 14:00

TORONTO, April 03, 2025 (GLOBE NEWSWIRE) -- TerrAscend Corp. ("TerrAscend" or the "Company") (TSX: TSND) (OTCQX: TSNDF) , a leading North American cannabis company, today announced that it will host a scheduled [...]

CRISPR Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

03/04/2025 - 14:00

ZUG, Switzerland and BOSTON, April 03, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today [...]

electroCore Named One of The Americas’ Fastest Growing Companies by the Financial Times

03/04/2025 - 14:00

ROCKAWAY, N.J., April 03, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, has been recognized by the Financial Times as one of “The Americas’ [...]

aTyr Pharma to Participate in April Investor Conferences

03/04/2025 - 14:00

SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA [...]

Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting

03/04/2025 - 13:35

MELBOURNE, Australia and SAN FRANCISCO, April 03, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying [...]

MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates

03/04/2025 - 13:00

Agreement with Hercules Capital significantly increases financial and operational strength, provides up to $500 million in capital with no dilution to shareholders, an attractive cost of capital and low operational and [...]

Boundless Bio to Participate in the Needham Virtual Healthcare Conference

03/04/2025 - 13:00

SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with [...]

Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences’ DecisionDx®-Melanoma Test

03/04/2025 - 13:00

Consistent with prior studies, published results from Castle’s DECIDE study show DecisionDx-Melanoma can both accurately identify patients with less than 5% risk of sentinel lymph node (SLN) positivity, who can safely [...]

Auron Presents New Preclinical Data for AUTX-703 in Small Cell Lung Cancer (SCLC)

03/04/2025 - 13:00

AUTX-703, a novel and potent oral KAT2A and KAT2B protein degrader, inhibits growth and induces profound, persistent cell state differentiation in SCLC models NEWTON, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Auron [...]

Ligandrol (LGD-4033) SARMs: Ligandrol Benefits, Ligandrol Results & Buy Ligandrol Pills Alternatives Ligan 4033 By CrazyBulk

03/04/2025 - 12:55

NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- “We’ve got several pro bodybuilding athletes ready and waiting to get to know you in our free private CrazyBulk community. And you’ll receive an invite to it the minute you [...]

Sai Life Sciences sets up Peptide Research Center in India

03/04/2025 - 11:58

HYDERABAD, India, April 03, 2025 (GLOBE NEWSWIRE) -- Sai Life Sciences Limited (BSE: 544306 I NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO) , has inaugurated [...]

Arialief: We Tested It—Here’s Our Honest Arialief Review “Shocking Conclusion”

03/04/2025 - 10:54

Is Arialief the breakthrough for nerve pain, numbness, and tingling through full-spectrum metabolic support? Read our real Arialief review and discover where to buy it online AURORA, Colo., April 03, 2025 (GLOBE [...]

Prime Biome: We Tested It—Here’s My Honest Prime Biome Review After 117 Days!

03/04/2025 - 10:35

Is Prime Biome’s “gut-skin synergy” the secret to beating bloating, revealing clearer skin, and maintaining steady weight management? Explore real reviews and where to buy. ST. PETERSBURG, Fla., April 03, 2025 (GLOBE [...]

Boehringer Ingelheim strengthens antibody-drug conjugate portfolio with new NBE Therapeutics R&D center in Basel

03/04/2025 - 09:00

CHF 27 million i nvestment signi ficantly bolsters Boehringer's ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company’s aim of transforming the lives of people with cancer . Boehringer [...]

Novo Nordisk announces changes in Executive Management

03/04/2025 - 08:00

Bagsværd, Denmark, 3 April 2025 – Novo Nordisk today announced the following changes in Executive Management. After a distinguished career of 28 years with Novo Nordisk, hereof seven years as executive vice president of [...]

LIfT BioSciences gains access to half a million allogeneic donors through collaboration with Gift of Life Biologics

03/04/2025 - 08:00

Press release LIfT BioSciences gains access to half a million allogeneic donors through collaboration with Gift of Life Biologics Access to extensive donor pool supports LIfT’s move into the clinic London, 03 April 2025 [...]

Informations relatives au nombre total de droits de vote et d’actions composant le capital

03/04/2025 - 08:00

Informations relatives au nombre total de droits de vote et d’actions composant le capital Nantes, le 3 avril 2025 – En application de l’article L. 233-8 II du Code de commerce et de l’article 223-16 du Règlement [...]

Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines

03/04/2025 - 07:00

Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines Designation granted for warm autoimmune hemolytic anemia and IgG4-related disease Rilzabrutinib is currently under [...]